RxDoctor Payments Data

Nancy Wells, NP

Women's Health · Bossier City, LANPI 1891709978

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $42,102 of the $46,623 with a category attached, or 90.3%. Organon accounts for 83.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $17,051 and has fallen 77.6% since, to $3,813 in 2025. Among women's health clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$46,623in general payments, 2019–2025

Across 251 payments — averaging $185.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$39K
  • Merck$5K
  • Daiichi Sankyo Inc.$551
  • AbbVie$500
  • Astellas Pharma US Inc$336
  • Evofem Biosciences, Inc.$224
  • plus $2K from 24 others

What the payments were for

  • Speaking & faculty fees$42,10290%
  • Travel & lodging$7392%
  • Food & beverage$3,6848%
  • Education$980%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,623 in reported general payments places this provider in the 95th percentile of 128 women's health providers in Louisiana.

See all women's health providers in Louisiana

Medicare billing

Part B allowed, 2024
$13,710
Medicare patients
110
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol41$1,796
Estradiol (Once Weekly)Estradiol16$1,130
Clobetasol Propionate16$160
Fluconazole13$40

Paid to pharmacies, not to this prescriber.

Other women's health in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →